REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical immuno-oncology and anti-cancer stem cell therapeutic candidates in a total of six presentations at the upcoming American Association for Cancer Research (AACR) Meeting to be held April 1-5, 2017 in Washington, DC.
Among the presentations will be three posters detailing preclinical data for OncoMed's novel anti-TIGIT (OMP-313M32) immuno-oncology therapeutic candidate. These will be the first data that the company has shared publicly for its anti-TIGIT antibody program. New data will also be presented on biomarker research associated with the Phase 1b portion of OncoMed's tarextumab (anti-Notch2/3, OMP-59R5) clinical trial in small cell lung cancer and OncoMed's preclinical GITRL-Fc trimer (OMP-336B11) program. In addition, xenograft data will be presented for anti-RSPO3 (OMP-131R10) in combination with taxane chemotherapy in colorectal cancer.
Read More: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=1015497
OncoMed Announces Multiple Abstracts Related to Anti-TIGIT Program Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2017
Via: ASN Kidney News
An interview with Leslie Trigg, President and CEO of Outset Medical
Silicon Valley venture pioneer Bill Draper will get a lifetime achievement award from the National Venture Capital Association next month.
Digital diabetes management company Omada Health has brought on federal policy veteran Lucia Savage as their new Chief Privacy and Regulatory Officer. Savage, who previously worked as Chief Privacy Officer at the Office of the National Coordinator for IT, will lead Omada’s legal and compliance team. In her new role, Savage will lead Omada’s regulatory strategy and ensure the privacy and security of the platform users’ personal health information. She will also work to advance Omada’s integration with EHRs and other patient record systems, in the aim to bring the company further into clinical processes.
OncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced it has enrolled and dosed the first patient in a Phase 1b clinical trial of its anti-DLL4/VEGF bispecific antibody (OMP-305B83) in combination with paclitaxel in patients with platinum-resistant ovarian cancer. OncoMed's anti-DLL4/VEGF bispecific antibody is designed to have anti-angiogenic, anti-cancer stem cell and immuno-modulatory activity.
Today’s medical therapy is tough competition, but new devices for use in CAS might tip the balance toward endovascular therapy, experts say.
HOLLYWOOD, Fla. — Foot-dragging by CMS and disagreements among professional societies are the most common reasons cited for why reimbursement for carotid stenting is limited in the United States, but there are more factors in play, a panel of experts said during a roundtable at the International Symposium on Endovascular Therapy.
Via: Fast Company
Omada Health is among the first digital health companies to receive reimbursement from the U.S. federal government for its online diabetes prevention program. Omada is aimed at the roughly 86 million Americans with prediabetes. The government support is a big step forward for chronic disease prevention: The Centers for Medicare & Medicaid Services has always reimbursed for screening diabetes, but not for companies and providers that help prevent the progression of the disease altogether. CMS's decision is also a big deal for other digital therapeutic startups, which essentially take established offline programs and bring them online to make them accessible for more patients.
Sean Duffy admits he’s been a health geek since he was a teenager. His obsession drew him to study neuroscience at Columbia University and it continued to pull at him even after he went to work at Google. In 2009, he decided to pursue a joint MD/MBA degree at Harvard. Between his first and second year, he served as health wellness domain specialist at the design firm IDEO. He realized during that summer the healthcare technology world was missing a vital element: design.
Using wireless devices that can track patients’ weight and diet, Utah's largest health system is trying to prevent the onset of diabetes among patients at a higher risk for the disease.